This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2006 May;2(3):103.

doi: 10.1200/JOP.2006.2.3.103.

Cost savings and luteinizing hormone-releasing hormone agonist

PMID: 20871707
PMCID: PMC2794587
DOI: 10.1200/JOP.2006.2.3.103

Cost savings and luteinizing hormone-releasing hormone agonist

Steven Tucker. J Oncol Pract. 2006 May.

. 2006 May;2(3):103.

doi: 10.1200/JOP.2006.2.3.103.

Author

PMID: 20871707
PMCID: PMC2794587
DOI: 10.1200/JOP.2006.2.3.103

No abstract available

PubMed Disclaimer

Figures

Figure 1
Steven Tucker, MD

See this image and copyright information in PMC

Similar articles

Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.
Chang SL, Liao JC, Shinghal R. Chang SL, et al. J Urol. 2009 Jul;182(1):255-60; discussion 261. doi: 10.1016/j.juro.2009.02.141. Epub 2009 May 17. J Urol. 2009. PMID: 19450844
A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.
Winfield H, Trachtenberg J. Winfield H, et al. J Urol. 1984 Jun;131(6):1107-9. doi: 10.1016/s0022-5347(17)50832-0. J Urol. 1984. PMID: 6427477 Clinical Trial.
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.
Merseburger AS, Björk T, Whitehouse J, Meani D. Merseburger AS, et al. J Comp Eff Res. 2015 Sep;4(5):447-53. doi: 10.2217/cer.14.82. Epub 2014 Dec 18. J Comp Eff Res. 2015. PMID: 25521079
Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.
Thompson IM, Zeidman EJ, Rodriguez FR. Thompson IM, et al. J Urol. 1990 Dec;144(6):1479-80. doi: 10.1016/s0022-5347(17)39774-4. J Urol. 1990. PMID: 2122011 Review.
Place of luteinizing hormone releasing hormone agonists in the treatment of prostatic cancer.
Dubernard JM, Marechal JM. Dubernard JM, et al. J Int Med Res. 1990;18 Suppl 1:26-30. doi: 10.1177/03000605900180S105. J Int Med Res. 1990. PMID: 2182354 Review.

See all similar articles

References

1. Wagmiller JA, Griggs JJ, Dick AW, et al: Individualized strategy for dosing luteinizing hormone–releasing hormone agonists for androgen-independent prostate cancer: Identification of outcomes and costs. J Oncol Pract 2:58-68, 2006 - PMC - PubMed
1. Centers for Medicare & Medicaid Services: Payment allowance limits for Medicare Part B drugs. January 2006 ASP Pricing File. http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp
1. Small EJ, Klein EA: Challenges and future directions in the prevention and management of prostate cancer. J Clin Oncol 23:8143-8145, 2005
1. Wang C, Catlin DH, Demers LM, et al: Measurement of total serum testosterone in adult men: Comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89:534-543, 2004 - PubMed
1. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39, 2004 - PubMed

LinkOut - more resources

Full Text Sources